NASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis $2.31 -0.08 (-3.15%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Protara Therapeutics Stock (NASDAQ:TARA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Protara Therapeutics alerts:Sign Up Key Stats Today's Range$2.24▼$2.4350-Day Range$2.13▼$3.9152-Week Range$2.09▼$7.82Volume432,112 shsAverage Volume883,235 shsMarket Capitalization$141.92 millionP/E RatioN/ADividend YieldN/APrice Target$26.25Consensus RatingModerate Buy Company Overview Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics. Its research and development activities focus on advancing these programs through clinical testing.AI Generated. May Contain Errors. Read More Protara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreTARA MarketRank™: 2.851837113675 of 5 starsProtara Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 234th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingProtara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialProtara Therapeutics has a consensus price target of $26.25, representing about 1,029.0% upside from its current price of $2.33.Amount of Analyst CoverageProtara Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Protara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.93% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protara Therapeutics has recently decreased by 46.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentProtara Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Protara Therapeutics is held by insiders.Percentage Held by Institutions38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARA Stock News HeadlinesHC Wainwright Has Bullish Outlook for TARA FY2026 EarningsNovember 13, 2026 | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Average Target Price of $26.25 According to AnalystsNovember 12, 2026 | americanbankingnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 17 at 1:00 AM | Paradigm Press (Ad)TARA Stock Earnings Estimates Decreased by HC WainwrightNovember 12, 2026 | americanbankingnews.comProtara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business UpdateNovember 6, 2026 | globenewswire.comProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on ...October 15, 2026 | finance.yahoo.comProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral SupportOctober 15, 2026 | globenewswire.comSee More Headlines TARA Stock Analysis - Frequently Asked Questions How have TARA shares performed this year? Protara Therapeutics' stock was trading at $5.33 at the beginning of 2026. Since then, TARA shares have decreased by 56.4% and is now trading at $2.3250. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) announced its earnings results on Friday, November, 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.02. When did Protara Therapeutics IPO? Protara Therapeutics (TARA) raised $79 million in an IPO on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at $12.00-$14.00 per share. Who are Protara Therapeutics' major shareholders? Top institutional investors of Protara Therapeutics include Baker BROS. Advisors LP (2.99%), Marshall Wace LLP (2.51%), Integral Health Asset Management LLC (2.03%) and State Street Corp (1.70%). Insiders that own company stock include Jacqueline Zummo, Jacqueline Zummo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Alibaba Group (BABA), Pfizer (PFE), Definium Therapeutics (DFTX), Intel (INTC) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/06/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TARA's financial health is in the Red zone, according to TradeSmith. TARA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TARA Previous SymbolNASDAQ:PRTO CIK1359931 Webwww.protaratx.com Phone(646) 844-0337Fax781-487-6729Employees51Year Founded2017Price Target and Rating Average Price Target for Protara Therapeutics$26.25 High Price Target$28.00 Low Price Target$24.00 Potential Upside/Downside+1,038.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.15% Return on Assets-42.75% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio10.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.29 per share Price / Book1.01Miscellaneous Outstanding Shares61,570,000Free Float56,891,000Market Cap$141.92 million OptionableOptionable Beta1.54 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TARA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.